Neurocrine Biosciences (NASDAQ:NBIX) Stock: Insider George Morrow Sells 300 Shares

Key Points

• Director George Morrow sold 300 shares for $44,700 at $149 per share under a pre-arranged Rule 10b5-1 plan, reducing his direct stake by 2.81% to 10,386 shares.
• Neurocrine reported quarterly results above expectations: earnings were $3.29 per share and revenue reached $1.12 billion, up 41.3% year over year. The company also raised its 2026 INGREZZA sales outlook to $2.9 billion–$2.925 billion.
• Shares rose 13.4% to $164.85 in Tuesday trading. Analysts’ consensus rating was Moderate Buy, with an average price target of $201.55.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director George Morrow sold 300 shares of the firm's stock in a transaction on Friday, October 30th. The stock was sold at an average price of $149.00, for a total value of $44,700.00. Following the sale, the director directly owned 10,386 shares of the company's stock, valued at approximately $1,547,514. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Trading Up 13.4%

Shares of NASDAQ NBIX traded up $19.50 during mid-day trading on Tuesday, reaching $164.85. The company had a trading volume of 4,056,875 shares, compared to its average volume of 1,234,742. The company has a 50-day moving average price of $146.49 and a two-hundred day moving average price of $147.45. The stock has a market cap of $16.76 billion, a PE ratio of 24.17, a P/E/G ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, beating the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business posted $2.04 earnings per share. Neurocrine Biosciences's revenue was up 41.3% compared to the same quarter last year. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently bought and sold shares of NBIX. Basecamp Wealth Advisors LLC lifted its position in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company's stock worth $31,000 after purchasing an additional 204 shares in the last quarter. Raleigh Capital Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company's stock worth $32,000 after purchasing an additional 191 shares during the period. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth approximately $33,000. Ascentis Independent Advisors purchased a new position in Neurocrine Biosciences during the first quarter valued at approximately $40,000. Finally, TrinityBridge Ltd purchased a new position in Neurocrine Biosciences during the second quarter valued at approximately $45,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Zacks Research cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 4th. Guggenheim initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 6th. They set a "buy" rating and a $207.00 price target on the stock. Truist Financial upped their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. TD Cowen raised their price objective on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, BMO Capital Markets decreased their price objective on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a "market perform" rating for the company in a research note on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $201.55.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.